Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nvidia Corp (NVDA) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

NVIDIA (NVDA) trades at $217.48, down 2.89% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $325.86. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding expectations, and demonstrates robust fundamentals including a net income margin of 62.97% and revenue growth to $130.50B in 2025.

Outlook remains positive driven by AI chip demand, but risks include high valuation multiples and competitive pressures. Investment opportunity hinges on sustained execution in AI infrastructure, while investors should monitor earnings consistency and market sentiment shifts.